Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Syndax Pharmaceuticals (Nasdaq: SNDX) will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET, accessible via the Events & Presentations page in the Investors section of its website or by domestic and international dial-in numbers.

A live webcast link (https://sndx-2q26.open-exchange.net/) and Conference ID Syndax2Q26 are provided. According to Syndax, a replay will be available on its website approximately 24 hours after the call and remain accessible for 90 days.

Argus Jul 28 session 24 alerts

-4.34% close to close 0.5x rel. volume Open Argus

Details

News Market Reaction – SNDX

$1.77B Mkt Cap at Peak Alert

On Jul 28, the day this news came out, SNDX closed 4.34% below the previous close. Our momentum scanner recorded 24 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 28 session.

Key Figures

Reporting period: Second quarter 2026 Announcement date: August 4, 2026 Conference call time: 4:30 p.m. ET +2 more

Reporting period

Second quarter 2026

Financial results announcement

Announcement date

August 4, 2026

Results and business update

Conference call time

4:30 p.m. ET

August 4, 2026

Replay availability

Approximately 24 hours

After the conference call

Replay duration

90 days

Following the conference call

Previous Conferences,earnings date Reports

2 past events · Latest: Apr 24

Same Type 2 events

1. Apr 24

   earnings date

   24h Move

   +1.9%

   Prior-quarter results announcement scheduled a conference call and webcast at 4:30 p.m. ET.

2. Feb 19

   earnings date

   24h Move

   +1.9%

   Fourth-quarter and full-year results announcement scheduled a conference call and webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

menin inhibitor, monoclonal antibody, csf-1 receptor, fda-approved

4 terms

menin inhibitor medical

"Revuforj® (revumenib), an FDA-approved menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

monoclonal antibody medical

"an FDA-approved monoclonal antibody that blocks the colony stimulating factor"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

csf-1 receptor medical

"blocks the colony stimulating factor 1 (CSF-1) receptor"

A cell-surface protein found mainly on certain immune cells that acts like a lock for signaling molecules such as colony-stimulating factor 1; when those molecules bind, the receptor tells the cell to grow, move or change behavior. As a biological control point in inflammation, tissue repair and some cancers, it is a common drug target; investors watch drug candidates and clinical results involving the receptor because they can affect the commercial and regulatory prospects of biotech companies.

fda-approved regulatory

"Revuforj® (revumenib), an FDA-approved menin inhibitor"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 4, 2026.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax2Q26
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-2q26.open-exchange.net/

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Syndax (Nasdaq: SNDX) report its Q2 2026 financial results?

Syndax will report its second quarter 2026 financial results on Tuesday, August 4, 2026. According to Syndax, the release will be accompanied by a business update and a conference call with management the same afternoon.

What time is the Syndax (SNDX) Q2 2026 earnings conference call on August 4, 2026?

The Syndax Q2 2026 earnings conference call is scheduled for 4:30 p.m. ET on August 4, 2026. According to Syndax, the call will follow the financial results release and business update earlier that day.

How can investors access the Syndax (SNDX) Q2 2026 earnings webcast on August 4, 2026?

Investors can access the Syndax Q2 2026 earnings webcast via the Events & Presentations page in the Investors section of its website. According to Syndax, a direct live link is https://sndx-2q26.open-exchange.net/ for the August 4, 2026 event.

What are the dial-in numbers for the Syndax (SNDX) Q2 2026 earnings call?

According to Syndax, the domestic dial-in number is 800-590-8290 and the international dial-in number is 240-690-8800. Participants should reference Conference ID Syndax2Q26 to join the Q2 2026 earnings call.

Will a replay be available for the Syndax (SNDX) Q2 2026 earnings call and for how long?

Yes, a replay of the Syndax Q2 2026 earnings call will be available on its website. According to Syndax, the replay will be posted about 24 hours after the call and remain accessible for 90 days in the Investors section.

Where can investors find more information about Syndax (SNDX) and its cancer therapies mentioned in the Q2 2026 update?

Investors can find more information on Syndax and its therapies at www.syndax.com. According to Syndax, the company highlights Revuforj (revumenib) and Niktimvo (axatilimab-csfr) and provides corporate updates on its website and social media channels.